Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...

Oculis Announces US Public Listing on NASDAQ Oculis Announces US Public Listing on NASDAQ Closing of business combination with European Biotech Acquisition Corp. creates Nasdaq-listed ophthalmology company, under the ticker “OCS”, with advanced...